CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 110 enrolled
Drug / intervention
gammaCore® (Vagus nerve stimulation)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04368156
NCT04368156N/ACompleted
CompareCT.gov

A Prospective, Randomized, Controlled Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms (SAVIOR)

Carlos Tornero·interventional·Posted Apr 29, 2020·Updated Jan 31, 2022

In Brief

A clinical study evaluating gammaCore® (Vagus nerve stimulation) for Covid-19. Completed, enrolled 110 participants across 1 site.

Detailed Summary

The purpose of this study is to asses the efficacy of the Gammacore device reducing the need for mechanical ventilation in patients diagnosed of Covid-19

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid-19
CountriesSpain
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedApr 29, 2020
Enrollment StartApr 20, 2020
Primary CompletionFeb 17, 2021
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 6.2 years ago

Interventions

gammaCore® (Vagus nerve stimulation)device

Vagus nerve stimulation using the gammacore neurostimulation device